The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma

MLA

A Baumann, et al. “The Aurora-Kinase A Phe31-Ile Polymorphism as Possible Predictor of Response to Treatment in Head and Neck Squamous Cell Carcinoma.” Oncotarget, vol. 9, no. 16, Jan. 2018, pp. 12769–80. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8e19b8ecd9c8dfda697e84cfef2bddd8&authtype=sso&custid=ns315887.

APA

A Baumann, Dominik Schüttler, Gero Brockhoff, Guido Piontek, Lena Gebel, Martina Rudelius, M Buchberger, Anja Pickhard, Gerhard Piendl, & Rudolf Reiter. (2018). The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma. Oncotarget, 9(16), 12769–12780.

Chicago

A Baumann, Dominik Schüttler, Gero Brockhoff, Guido Piontek, Lena Gebel, Martina Rudelius, M Buchberger, Anja Pickhard, Gerhard Piendl, and Rudolf Reiter. 2018. “The Aurora-Kinase A Phe31-Ile Polymorphism as Possible Predictor of Response to Treatment in Head and Neck Squamous Cell Carcinoma.” Oncotarget 9 (16): 12769–80. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8e19b8ecd9c8dfda697e84cfef2bddd8&authtype=sso&custid=ns315887.